Long-term Implications of Reocclusion on Left Ventricular Size and Function After Successful Thrombolysis for First Anterior Myocardial Infarction

Nijland, Francisca; Kamp, Otto; Verheugt, Freek W.A.; Veen, Gerrit; Visser, Cees A.

doi:10.1161/01.cir.95.1.111

Cited by 39 publications

(20 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18 Left ventricular volumes in end-diastole and end-systole were determined, using a system for off-line analysis (ImageVue, Nova Microsonics Inc., NJ, USA) using Simpson's biplane method. 19 Doppler measurements were also analysed with this system.…”

Section: Analysis Of Echocardiographymentioning

confidence: 99%

Effects of high-dose insulin infusion on left ventricular function in normal subjects

Klein

Campen²,

Sieswerda³

et al. 2010

NHJL

View full text Add to dashboard Cite

Background. Only a few studies have reported on the effect of high-dose insulin (HDI) infusion on cardiac function in healthy volunteers. Methods. We studied ten healthy volunteers with low-dose dobutamine (LDD, 10 mug/kg/min) echo-cardio-graphy and HDI echocardiography (insulin administration for one hour) by volume and Doppler analysis. Results. During LDD, cardiac output increased from 5.7+/-1.3 l/min to 9.0+/-2.1 l/min (p<0.001) and during HDI from 5.5+/-1.2 l/min to 6.2+/-1.1 l/min (p=0.048). Increase was not only due to increase in frequency, which was only present in the LDD study, but also due to increase in stroke volume (from 82+/-15 ml to 110+/-23 ml, p<0.001 during LDD and from 82+/-16 ml to 93+/-24 ml, p=0.014 during HDI). The increase in stroke volume was the result of a decrease in end-systolic volume with an unchanged end-diastolic volume. Conclusion. High-dose insulin infusion results in increased cardiac output by improving systolic myocardial function. (Neth Heart J 2010;18:183-9.).

show abstract

Section: Analysis Of Echocardiographymentioning

confidence: 99%

Effects of high-dose insulin infusion on left ventricular function in normal subjects

Klein

Campen²,

Sieswerda³

et al. 2010

NHJL

View full text Add to dashboard Cite

show abstract

“…We cannot, however, exclude that a later follow-up would have given different results. Indeed, in a recent analysis of a subset of the patients enrolled in the APRICOT study, Nijland et al 24 have shown that late reocclusion of the IRA is associated with left ventricular dilatation 5 years after first MI.…”

Section: Late Reocclusion and Left Ventricular Functionmentioning

confidence: 99%

Angiographically Documented Late Reocclusion After Successful Coronary Angioplasty of an Infarct-Related Lesion Is a Powerful Predictor of Long-Term Mortality

et al. 1999

View full text Add to dashboard Cite

Background-Late reocclusion of an infarct-related artery (IRA) that was patent in the early days after acute myocardial infarction (MI) is a frequent event; the reocclusion rate may be as high as 30%. Few studies have been designed to analyze the impact of late reocclusion of the IRA on late survival. Methods and Results-We studied 528 patients who all had a patent IRA after a successful PTCA procedure 10Ϯ6 days after MI and who underwent systematic 6-month angiographic follow-up to assess late patency of the IRA. We compared long-term survival of patients with and without late reocclusion. Based on the results of 6-month follow-up angiography, 2 groups of patients were defined: (1) 90 patients (17%) with reocclusion (Thrombolysis In Myocardial Infarction [TIMI] flow 0 or 1) and (2) 438 patients (83%) without reocclusion. Long-term clinical follow-up was obtained for all 528 patients at a median of 5.7 years after follow-up angiography (6.4 years after PTCA). The overall actuarial 8-year total mortality rate was 13%. At the end of follow-up, there were 35 deaths (8%) among the 438 patients without reocclusion and 18 deaths (20%) among the 90 patients with reocclusion (Pϭ0.002). The actuarial 8-year total mortality rate was 10% in patients without reocclusion and 28% in patients with reocclusion (Pϭ0.0003). The actuarial cardiovascular mortality rate was 7% in patients without reocclusion and 25% in patients with reocclusion (PϽ0.0001).The impact of reocclusion on long-term mortality was greater in patients with anterior MI. Conclusions-Late IRA patency is strongly associated with long-term survival after MI. These observations should encourage prospective studies to evaluate the impact of strategies designed to prevent late reocclusion in postinfarction patients. (Circulation. 1999;99:2243-2250.)

show abstract

“…Second, it is also possible that, as shown in previous trials [5], this mortality reduction was a result of a reduction in reocclusion with stent use [11]. Several studies have suggested that sustained patency was associated with better left ventricular remodeling (less left ventricular dilatation), improved electrical stability, and the provision of collateral vessels to other coronary beds for protection against future events [12,13]. In fact, infarct-related artery patency at 6 months is strongly associated with long-term survival (6 years) after MI [14].…”

Section: Discussionmentioning

confidence: 93%

Long-term outcome of acute myocardial infarction patients treated with stents versus balloon angioplasty: Results from randomized trials

Kaneda

Hiroe

Tanaka

et al. 2009

International Journal of Cardiology

View full text Add to dashboard Cite

Long-term Implications of Reocclusion on Left Ventricular Size and Function After Successful Thrombolysis for First Anterior Myocardial Infarction

Cited by 39 publications

References 53 publications

Effects of high-dose insulin infusion on left ventricular function in normal subjects

Effects of high-dose insulin infusion on left ventricular function in normal subjects

Angiographically Documented Late Reocclusion After Successful Coronary Angioplasty of an Infarct-Related Lesion Is a Powerful Predictor of Long-Term Mortality

Long-term outcome of acute myocardial infarction patients treated with stents versus balloon angioplasty: Results from randomized trials

Contact Info

Product

Resources

About